MMWR Morb Mortal Wkly Rep. 2011 Nov 4;60(43):1487-92.
Overdose deaths involving opioid pain relievers (OPR), also known as opioid analgesics, have increased and now exceed deaths involving heroin and cocaine combined. This report describes the use and abuse of OPR by state.
CDC analyzed rates of fatal OPR overdoses, nonmedical use, sales, and treatment admissions.
In 2008, drug overdoses in the United States caused 36,450 deaths. OPR were involved in 14,800 deaths (73.8%) of the 20,044 prescription drug overdose deaths. Death rates varied fivefold by state. States with lower death rates had lower rates of nonmedical use of OPR and OPR sales. During 1999--2008, overdose death rates, sales, and substance abuse treatment admissions related to OPR all increased substantially.
The epidemic of overdoses of OPR has continued to worsen. Wide variation among states in the nonmedical use of OPR and overdose rates cannot be explained by underlying demographic differences in state populations but is related to wide variations in OPR prescribing.
Health-care providers should only use OPRs in carefully screened and monitored patients when non-OPR treatments are insufficient to manage pain. Insurers and prescription drug monitoring programs can identify and take action to reduce both inappropriate and illegal prescribing. Third-party payers can limit reimbursement in ways that reduce inappropriate prescribing, discourage efforts to obtain OPR from multiple health-care providers, and improve clinical care. Changes in state laws that focus on the prescribing practices of health-care providers might reduce prescription drug abuse and overdoses while still allowing safe and effective pain treatment.
涉及阿片类止痛药(OPR)的药物过量死亡人数不断增加,现已超过海洛因和可卡因死亡人数之和。本报告描述了各地区对 OPR 的使用和滥用情况。
疾病预防控制中心分析了致命 OPR 药物过量、非医疗用途、销售和治疗入院率。
2008 年,美国有 36450 人因药物过量而死亡。在 20044 例与处方药物过量有关的死亡中,OPR 涉及 14800 例(73.8%)死亡。各州的死亡率相差五倍。死亡率较低的州,OPR 的非医疗使用和销售率也较低。1999 年至 2008 年期间,OPR 相关的药物过量死亡率、销售和物质滥用治疗入院率均大幅上升。
OPR 药物过量的流行情况继续恶化。各州之间在 OPR 的非医疗使用和过量率方面存在巨大差异,这不能用各州人口中潜在的人口统计学差异来解释,而是与 OPR 处方的广泛差异有关。
医疗保健提供者只有在非 OPR 治疗不足以控制疼痛的情况下,才能在经过仔细筛选和监测的患者中使用 OPR。保险公司和处方药物监测计划可以识别并采取行动,减少不适当和非法的处方。第三方付款人可以通过限制报销的方式减少不适当的处方,阻止从多个医疗保健提供者获取 OPR 的努力,并改善临床护理。集中于医疗保健提供者处方实践的州法律的变化可能会减少处方药物滥用和过量,同时仍允许安全有效的疼痛治疗。